Abiraterone triplet therapy improves long-term survival in metastatic prostate cancer
Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification.
Read original article on The Medical News →Related news
-
New animal model offers more precise way to study calorie-burning brown fat
United Kingdom
-
53 Orangutans Rescued from Fires in Borneo, With Many Rewilded to Forest Preserves Across the Island
United Kingdom
-
Can psychedelics soothe an overactive immune system? New meta-analysis investigates
United Kingdom
-
Flood Worries? Tape Can Block 99% of Water Compared to Expensive Sandbags That Break Your Back
United Kingdom
-
Postpartum recovery window may play a critical role in maternal aging and long-term health
United Kingdom
-
A Chance Meeting in a Chinese Restaurant Saved a Man’s Life – As Everything Happens for a Reason
United Kingdom
-
Scientists reveal the hidden danger of missing blood pressure medication
United States
-
The Invisible Layer: Electromagnetic Exposure and Human Health in the Built Environment
United States